Comparison of efficacy of plasma exchange versus intravenous immunoglobulin as an add‐on therapy in acute attacks of neuromyelitis optica spectrum disorder

Fuente: Wiley Open Access
Salvato in:
Dettagli Bibliografici
Autori principali: Garima Siwach, Rekha Hans, Aastha Takkar, Chirag Kamal Ahuja, Divjot Singh Lamba, Vivek Lal, Ratti Ram Sharma
Natura: Artículo Open Access
Pubblicazione: Wiley 2024
Soggetti:
Accesso online:
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!
_version_ 1867011078345457664
author Garima Siwach
Rekha Hans
Aastha Takkar
Chirag Kamal Ahuja
Divjot Singh Lamba
Vivek Lal
Ratti Ram Sharma
author_facet Garima Siwach
Rekha Hans
Aastha Takkar
Chirag Kamal Ahuja
Divjot Singh Lamba
Vivek Lal
Ratti Ram Sharma
Garima Siwach
Rekha Hans
Aastha Takkar
Chirag Kamal Ahuja
Divjot Singh Lamba
Vivek Lal
Ratti Ram Sharma
collection Wiley Open Access
contents Comparison of efficacy of plasma exchange versus intravenous immunoglobulin as an add‐on therapy in acute attacks of neuromyelitis optica spectrum disorder Garima Siwach Rekha Hans Aastha Takkar Chirag Kamal Ahuja Divjot Singh Lamba Vivek Lal Ratti Ram Sharma Journal of Clinical Apheresis AbstractIntroductionPlasma exchange (PE) is considered a Category II option for the treatment of acute attacks and relapse cases of neuromyelitis optica spectrum disorder (NMOSD). However, neurologists are also considering intravenous immunoglobulins (IVIg) as an add‐on therapy for this disorder.AimsThe aim of this study is to evaluate the efficacy of PE in acute attacks of NMOSD when compared with IVIg, in terms of improvement in the Expanded disability status scale (EDSS) and activities of daily living (ADL) scale score and levels of anti‐Aquaporin P4 (AQP4) antibody in seropositive patients.MethodsWe enrolled 43 NMOSD patients in two groups: Group 1 (n = 29) received steroids and PE, and Group 2 (n = 14) received steroids with IVIg. The baseline EDSS and ADL scores were recorded and compared with scores at the end of therapy, 4 weeks, and 3 months after. Also, anti‐AQP4 antibody was measured at baseline and post‐therapy in seropositive patients of both groups.ResultsWe observed a significant difference in EDSS (p = 0.00) and ADL score (p = 0.00) at day 10 and 3 months in both groups. However, no significant difference in EDSS, as well as ADL score from baseline (p = 0.83; p = 0.25) to 3 months (p = 0.85; p = 0.19), was observed when delta change of score at 3 months was compared across the two groups (p = 0.39; p = 0.52). We observed improved visual acuity in both groups with mild improvement in findings of magnetic resonance imaging at 3 months. We observed a significant decline in AQP4 antibody concentration (at day 10) in group 1 seropositive patients (p = 0.013) with improved EDSS (p = 0.027) and ADL scores (p = 0.026) of these patients.ConclusionsPE should be considered as a choice of an add‐on therapy in anti‐AQP4 antibody‐positive NMOSD patients compared with IVIg as it is more effective in reducing antibody concentrations. 10.1002/jca.22129 http://onlinelibrary.wiley.com/termsAndConditions#vor
doi_str_mv 10.1002/jca.22129
format Artículo Open Access
id wiley_oa_10_1002_jca_22129
institution Wiley Open Access
license_str_mv http://onlinelibrary.wiley.com/termsAndConditions#vor
publishDate 2024
publisher Wiley
record_format wiley_oa
spellingShingle Comparison of efficacy of plasma exchange versus intravenous immunoglobulin as an add‐on therapy in acute attacks of neuromyelitis optica spectrum disorder
Garima Siwach
Rekha Hans
Aastha Takkar
Chirag Kamal Ahuja
Divjot Singh Lamba
Vivek Lal
Ratti Ram Sharma
Journal of Clinical Apheresis
Comparison of efficacy of plasma exchange versus intravenous immunoglobulin as an add‐on therapy in acute attacks of neuromyelitis optica spectrum disorder Garima Siwach Rekha Hans Aastha Takkar Chirag Kamal Ahuja Divjot Singh Lamba Vivek Lal Ratti Ram Sharma Journal of Clinical Apheresis AbstractIntroductionPlasma exchange (PE) is considered a Category II option for the treatment of acute attacks and relapse cases of neuromyelitis optica spectrum disorder (NMOSD). However, neurologists are also considering intravenous immunoglobulins (IVIg) as an add‐on therapy for this disorder.AimsThe aim of this study is to evaluate the efficacy of PE in acute attacks of NMOSD when compared with IVIg, in terms of improvement in the Expanded disability status scale (EDSS) and activities of daily living (ADL) scale score and levels of anti‐Aquaporin P4 (AQP4) antibody in seropositive patients.MethodsWe enrolled 43 NMOSD patients in two groups: Group 1 (n = 29) received steroids and PE, and Group 2 (n = 14) received steroids with IVIg. The baseline EDSS and ADL scores were recorded and compared with scores at the end of therapy, 4 weeks, and 3 months after. Also, anti‐AQP4 antibody was measured at baseline and post‐therapy in seropositive patients of both groups.ResultsWe observed a significant difference in EDSS (p = 0.00) and ADL score (p = 0.00) at day 10 and 3 months in both groups. However, no significant difference in EDSS, as well as ADL score from baseline (p = 0.83; p = 0.25) to 3 months (p = 0.85; p = 0.19), was observed when delta change of score at 3 months was compared across the two groups (p = 0.39; p = 0.52). We observed improved visual acuity in both groups with mild improvement in findings of magnetic resonance imaging at 3 months. We observed a significant decline in AQP4 antibody concentration (at day 10) in group 1 seropositive patients (p = 0.013) with improved EDSS (p = 0.027) and ADL scores (p = 0.026) of these patients.ConclusionsPE should be considered as a choice of an add‐on therapy in anti‐AQP4 antibody‐positive NMOSD patients compared with IVIg as it is more effective in reducing antibody concentrations. 10.1002/jca.22129 http://onlinelibrary.wiley.com/termsAndConditions#vor
title Comparison of efficacy of plasma exchange versus intravenous immunoglobulin as an add‐on therapy in acute attacks of neuromyelitis optica spectrum disorder
topic Journal of Clinical Apheresis
url https://onlinelibrary.wiley.com/doi/10.1002/jca.22129